tradingkey.logo

Cencora Q1 EPS beats estimates as margins rise; keeps FY EPS forecast

ReutersFeb 4, 2026 11:38 AM


Overview

  • Pharmaceutical solutions firm's fiscal Q1 revenue rose 5.5% yr/yr, slightly missing expectations

  • Adjusted EPS for fiscal Q1 beat analyst expectations

  • Company completed acquisition of OneOncology, enhancing specialty MSO footprint


Outlook

  • Cencora raises adjusted operating income growth forecast to 11.5% to 13.5% for fiscal 2026

  • Company reaffirms fiscal 2026 adjusted diluted EPS guidance range at $17.45 to $17.75

  • Cencora expects fiscal 2026 revenue growth of 7% to 9%


Result Drivers

  • SEGMENT GROWTH - Revenue growth driven by 5% increase in U.S. Healthcare Solutions and 9.6% increase in International Healthcare Solutions

  • ACQUISITION IMPACT - Completion of OneOncology acquisition raised adjusted operating income guidance

  • GROSS PROFIT MARGIN - Increase in gross profit margin attributed to higher sales and acquisition of RCA


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Slight Miss*

$85.93 bln

$86.03 bln (12 Analysts)

Q1 Adjusted EPS

Beat

$4.08

$4.04 (15 Analysts)

Q1 EPS

$2.87

Q1 Net Income

$566.13 mln

Q1 Adjusted Operating Income

Beat

$1.10 bln

$1.06 bln (11 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Press Release: ID:nBw5MGNFDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI